South Dakota Investment Council Buys 22,900 Shares of Progyny, Inc. $PGNY

South Dakota Investment Council increased its stake in Progyny, Inc. (NASDAQ:PGNY) by 20.0% in the first quarter, Holdings Channel.com reports. The firm owned 137,524 shares of the company’s stock after purchasing an additional 22,900 shares during the quarter. South Dakota Investment Council’s holdings in Progyny were worth $2,335,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Easterly Investment Partners LLC raised its stake in shares of Progyny by 197.4% in the 4th quarter. Easterly Investment Partners LLC now owns 146,013 shares of the company’s stock valued at $3,750,000 after purchasing an additional 96,912 shares during the period. First Eagle Investment Management LLC boosted its position in shares of Progyny by 40.2% during the fourth quarter. First Eagle Investment Management LLC now owns 212,612 shares of the company’s stock worth $5,460,000 after buying an additional 60,912 shares during the period. Simcoe Capital LLC acquired a new position in shares of Progyny during the fourth quarter worth about $3,902,000. CenterBook Partners LP grew its holdings in shares of Progyny by 36.2% during the fourth quarter. CenterBook Partners LP now owns 578,171 shares of the company’s stock worth $14,847,000 after buying an additional 153,778 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in shares of Progyny by 92.6% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 145,647 shares of the company’s stock worth $3,750,000 after buying an additional 70,021 shares in the last quarter. Institutional investors own 94.93% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PGNY. Citigroup reissued an “outperform” rating on shares of Progyny in a research report on Monday, May 11th. Wall Street Zen downgraded Progyny from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. Barclays reaffirmed an “equal weight” rating and set a $34.00 price target (up from $27.00) on shares of Progyny in a research note on Tuesday. Bank of America lifted their price objective on shares of Progyny from $29.00 to $31.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. Finally, Zacks Research raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Progyny presently has an average rating of “Moderate Buy” and an average price target of $33.25.

Insider Buying and Selling

In related news, EVP Allison Swartz sold 1,199 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $25.02, for a total transaction of $29,998.98. Following the transaction, the executive vice president directly owned 83,316 shares in the company, valued at approximately $2,084,566.32. The trade was a 1.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin K. Gordon sold 5,500 shares of the company’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $24.99, for a total transaction of $137,445.00. Following the sale, the director directly owned 9,318 shares in the company, valued at $232,856.82. This trade represents a 37.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 36,916 shares of company stock worth $939,875 in the last quarter. 9.90% of the stock is owned by company insiders.

Progyny Stock Performance

NASDAQ:PGNY opened at $31.13 on Friday. The stock’s 50-day simple moving average is $28.55 and its 200 day simple moving average is $23.26. The company has a market cap of $2.44 billion, a P/E ratio of 40.43, a P/E/G ratio of 2.50 and a beta of 1.01. Progyny, Inc. has a 52-week low of $16.10 and a 52-week high of $33.06.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.26 by $0.24. The firm had revenue of $328.50 million during the quarter, compared to analysts’ expectations of $326.46 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The business’s quarterly revenue was down 26.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, equities analysts predict that Progyny, Inc. will post 1.19 earnings per share for the current fiscal year.

Progyny declared that its Board of Directors has approved a share repurchase plan on Tuesday, May 26th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to buy up to 10.3% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.